Department of Health Sciences, University of Florence, Florence, Italy.
Clinical Pharmacopsychology Laboratory, University of Florence, Florence, Italy.
Psychol Med. 2022 Jul;52(9):1621-1628. doi: 10.1017/S0033291722001507. Epub 2022 Jun 3.
Staging has been increasingly used in unipolar depression since its introduction in the nineties. Several models are available, but their differential features and implications are not completely clear. We systematically reviewed: (a) staging models of longitudinal development of unipolar depression; (b) staging models of treatment-resistant unipolar depression; (c) their applications. MEDLINE, PsycINFO, EMBASE, and Web of Science were examined according to PRISMA guidelines from inception to December 2021. Search terms were: 'stage/staging', combined using the Boolean 'AND' operator with 'psychiatric disorder/mental disorder/depressive/mood disorder'. A total of 169 studies were identified for inclusion: 18 described staging models or applications, 151 described treatment-resistant staging models or applications. Staging models of longitudinal development were found to play a key role in formulating sequential treatment, with particular reference to the use of psychotherapy after pharmacotherapy. Staging methods based on treatment resistance played a crucial role in setting entry criteria for randomized clinical trials and neurobiological investigations. Staging is part of clinimetrics, the science of clinical measurements, and its role can be enhanced by its association with other clinimetric strategies, such as repeated assessments, organization of problematic areas, and evaluation of phenomena that may affect responsiveness. In research, it may allow to identify more homogeneous populations in terms of treatment history that may diminish the likelihood of spurious results in comparisons. In clinical practice, the use of staging in a clinimetric perspective allows clinicians to make full use of the information that is available for an individual patient at a specific time.
自 90 年代引入以来,分期已越来越多地用于单相抑郁症。有几种模型可用,但它们的不同特征和意义尚不完全清楚。我们系统地回顾了:(a)单相抑郁症纵向发展的分期模型;(b)单相抑郁症治疗抵抗的分期模型;(c)它们的应用。根据 PRISMA 指南,从开始到 2021 年 12 月,我们检查了 MEDLINE、PsycINFO、EMBASE 和 Web of Science。检索词为:“stage/staging”,使用布尔运算符“AND”与“psychiatric disorder/mental disorder/depressive/mood disorder”相结合。共确定了 169 项符合纳入标准的研究:18 项描述了分期模型或应用,151 项描述了治疗抵抗的分期模型或应用。纵向发展的分期模型在制定序贯治疗方面发挥了关键作用,特别是在药物治疗后使用心理治疗方面。基于治疗抵抗的分期方法在为随机临床试验和神经生物学研究设定纳入标准方面发挥了至关重要的作用。分期是临床测量学的一部分,即临床测量的科学,通过与其他临床测量策略(如重复评估、问题区域的组织以及评估可能影响反应性的现象)的结合,可以增强其作用。在研究中,它可以根据治疗史确定更同质的人群,从而减少比较中出现虚假结果的可能性。在临床实践中,从临床测量学的角度使用分期可以使临床医生充分利用特定时间点为个体患者提供的信息。